|
|
Other links at Articles > Diabetes and Endocrinology |
| 1. |
Why and When to Implement Incretin Therapy
|
|
|
Two agents are currently available in the United States that act upon the incretin hormone system -- exenatide (Byetta), a twice-daily glucagon-like peptide-1 (GLP-1) receptor agonist, and sitagliptin (Januvia), a dipeptidyl peptidase-4 (DPP-4) inhibitor.
|
| 3. |
Elevated Fracture Risk Seen With HIV Infection
|
|
|
The results of a population-based study suggest that HIV-infected patients are at increased risk for a variety of fractures compared with their non-infected counterparts. Reuters Health Information
|
| 5. |
FDA Safety Changes: DDAVP and Januvia
|
|
|
The FDA has approved revisions to the safety labeling for desmopressin acetate nasal spray, injection, rhinal tube, and tablets (DDAVP), and sitagliptin phosphate tablets (Januvia). Medscape Medical News
|
|
|
